FHTX at a glance
Foghorn Therapeutics Inc. (FHTX, SEC CIK 1822462) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as June 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.9 million (up 36.8% from FY2024) and a net loss of $74.3 million. Diluted EPS was -$1.18.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Foghorn Therapeutics Inc. (FHTX) shares worth $38.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $30.9M
- +36.8% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $38.1M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Collaboration revenue $83.5M, up $75.4M YoY from $8.2M, including $74.1M cumulative catch-up adjustment
- Operating margin 67.8% vs negative 226.9% YoY, with operating income $56.6M vs loss of $18.5M
- Lilly partnered programs, largest R&D line, $4.6M, down $2.2M YoY; early development costs increased $1.7M
- Cash, equivalents and marketable securities $156.2M; nine-month operating cash outflow $61.4M
- Near-term cost reductions expected from pipeline reprioritization and 40% workforce reduction; cash runway expected at least twelve months
Risk Factors
- New clinical-development risk: FHD-909 and SMARCA2 degrader halted after Phase 1 data review
- New workforce-reduction risk: strategic reprioritization cut approximately an undisclosed percentage of employees
- Regulatory risk: IRS audit opened for tax year 2023, with potential outcomes under evaluation
- Financial risk: accumulated deficit $601.4 million despite $31.1 million nine-month net income
- Collaboration concentration risk: $74.1 million revenue recognized from Lilly program reprioritization નિર્ણ
AI summary of the FHTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for the quarter ended September 30, 2026 announced
- Press release contains the substantive financial figures and operating updates
Item 7.01: Regulation FD Disclosure
- November 2026 investor presentation furnished as Exhibit 99.2
- Presentation likely contains updated company, pipeline, or strategic information for investor meetings
Item EX-99.1: Item EX-99.1
- Q3 2026 collaboration revenue $83.5M vs $8.2M, including $74.1M cumulative catch-up from discontinued FHD-909 and SMARCA2 programs
- Net income $58.2M, or $0.80 diluted EPS, vs $15.8M loss and $0.25 loss per share in Q3 2025
Item EX-99.2: Item EX-99.2
- Investor presentation outlines wholly owned pipeline spanning oncology, I&I, and induced-proximity programs
- Cash and equivalents $156.2M as of 09/30/2026, supporting runway into second half of 2029
Item 7.01: Regulation FD Disclosure
- Foghorn will not advance FHD-909 into the clinical trial expansion phase
- Strategic prioritization signals reduced development focus on FHD-909
Item 2.05: Costs Associated with Exit or Disposal Activities
- FHD-909 Phase 1 will not advance to expansion after clinical-data review
- Lilly collaboration activities no longer anticipated, removing a partnered development path
Item EX-99.1: Item EX-99.1
- Foghorn and Lilly will not advance FHD-909 after Phase 1 data failed to demonstrate sufficient efficacy
- Selective SMARCA2 degrader collaboration also ending, removing a partnered development path
Item 2.02: Results of Operations and Financial Condition
- Foghorn announced financial results for the quarter ended June 30, 2026
- Results released August 6, 2026, with detailed figures in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- August 2026 investor presentation, signaling updated corporate messaging for investor meetings
- Exhibit 99.2 may contain material pipeline, clinical, financial, or strategic updates relevant to valuation
Item EX-99.1: Item EX-99.1
- Q2 collaboration revenue $16.1M vs $7.6M, boosted by $14.2M cumulative catch-up tied to Lilly research-term expiration
- Net loss narrowed to $7.2M from $17.9M, while R&D fell to $18.5M from $21.8M
AI summaries of FHTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FHTX
Don't miss the next FHTX filing
- Alerts as it files. A push when FHTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FHTX, by share count.
- Ask anything. An AI agent that reads every FHTX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SMITH IAN F | A | Jun 24, 2026 | 28,000 | $4.08 |
| Mendelsohn Michael | A | Jun 24, 2026 | 28,000 | $4.08 |
| Cole Douglas G. | A | Jun 24, 2026 | 28,000 | $4.08 |
| PARSHALL B LYNNE | A | Jun 24, 2026 | 28,000 | $4.08 |
| Duty Stuart | A | Jun 24, 2026 | 28,000 | $4.08 |
| Lynch Thomas J. Jr. | A | Jun 24, 2026 | 28,000 | $4.08 |
| Gallagher Neil | A | Jun 24, 2026 | 28,000 | $4.08 |
| Biller Scott | A | Jun 24, 2026 | 28,000 | $4.08 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $34.2M | $22.6M | $30.9M |
| Operating Income | - | -$102.7M | -$86.4M |
| Net Income | -$98.4M | -$86.6M | -$74.3M |
| Op. Margin | - | -454.3% | -279.5% |
| Net Margin | -288.2% | -383.2% | -240.3% |
| Balance Sheet | |||
| Total Assets | - | $284.0M | $198.1M |
| Equity | - | -$45.5M | -$108.5M |
| ROE | - | 190.3% | 68.5% |
| Per Share | |||
| EPS | $-2.34 | $-1.58 | $-1.18 |
| Cash Flow | |||
| Operating CF | - | -$100.4M | -$86.1M |
| CapEx | $1.2M | $906K | $50K |
Source: XBRL data in Foghorn Therapeutics Inc. (FHTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate FHTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $38.1M |
| Q2 2026 | 23 | $75.1M |
| Q1 2026 | 23 | $73.2M |
| Q4 2025 | 22 | $80.3M |
| Q3 2025 | 20 | $69.3M |
| Q2 2025 | 20 | $65.1M |
| Q1 2025 | 18 | $41.4M |
| Q4 2024 | 13 | $52.5M |
- JPMorgan Chase & Co+623.1K (+3049%)
- BlackRock+438.4K (+17%)
- Vanguard Capital Management LLC+91.6K (+6%)
- Morgan Stanley+80.7K (+88%)
- Goldman Sachs Group+70.4K (+43%)
- Ameriprise Financial−430.1K (-77%)
- Citadel Advisors LLC−52.3K (-33%)
- AQR Capital Management−28.9K (-44%)
- Wells Fargo & Co−21.9K (-62%)
- Citigroup−15.2K (-82%)
- Prudential Financial+87.0K
- FMR LLC (Fidelity)−5.71M
Source: 13F-HR filings on SEC EDGAR (aggregated from 162 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FHTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 4 | Apr 13, 2026 | - | - | - |
| 10-K | Mar 11, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 11, 2026 | - | Analysis | - |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| 4 | Feb 6, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
FHTX SEC filings: frequently asked questions
Which institutions hold FHTX stock?
As of September 30, 2026, the largest Foghorn Therapeutics Inc. (FHTX) holders among the 13F filers tracked by SignalX were BlackRock ($10.9 million), Raymond James Financial ($8.9 million), Vanguard Capital Management LLC ($5.7 million), State Street Corp ($2.5 million), JPMorgan Chase & Co ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FHTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.9 million (up 36.8% from FY2024) and a net loss of $74.3 million. Diluted EPS was -$1.18. The figures come from the XBRL data in the 10-K.
What did FHTX report in its latest 8-K?
Foghorn Therapeutics Inc. (FHTX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results for the quarter ended September 30, 2026 announced.
What are the latest FHTX SEC filings?
Foghorn Therapeutics Inc. (FHTX) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on June 25, 2026.
What is FHTX's SEC CIK number?
Foghorn Therapeutics Inc. (FHTX)'s SEC Central Index Key (CIK) is 1822462. EDGAR lists every FHTX filing under that number.
Ask anything about FHTX
The research agent reads FHTX's filings, financials, insider trades and 13F holders, then answers with sources.